Recombinant murine growth hormone particles are more immunogenic with intravenous than subcutaneous administration

Journal of Pharmaceutical Sciences

Volumn 103, Issue 1, 2014, Pages 128-139

  Christie, Merry ^a   Torres, Raul M ^b   Kedl, Ross M ^b   Randolph, Theodore W ^c   Carpenter, John F ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c University of Colorado at Boulder   (United States)

Author keywords

immune response; immunology; microparticles; nanoparticles; particle size; proteins

Indexed keywords

IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3 ANTIBODY; NANOPARTICLE; RECOMBINANT GROWTH HORMONE; GROWTH HORMONE; IMMUNOGLOBULIN G; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; FEMALE; GEL PERMEATION CHROMATOGRAPHY; IMMUNE RESPONSE; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; ANIMAL; ANTIBODY PRODUCTION; BAGG ALBINO MOUSE; C57BL MOUSE; HYPODERMOCLYSIS; IMMUNOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; PROCEDURES; WEIGHT GAIN;

ANIMALS; ANTIBODY FORMATION; CHEMISTRY, PHARMACEUTICAL; FEMALE; GROWTH HORMONE; HYPODERMOCLYSIS; IMMUNOGLOBULIN G; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PARTICLE SIZE; RECOMBINANT PROTEINS; WEIGHT GAIN;

EID: 84890525954     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23794     Document Type: Article

References (67)

1. Marshall SA, Lazar GA, Chirino AJ, Desjarlais JR,. 2003. Rational design and engineering of therapeutic proteins. Drug Discov Today 8 (5): 212-221.
2. Schellekens H., 2002. Immunogenicity of therapeutic proteins: Clinical implications and future prospects. Clin Ther 24 (11): 1720-1740.
3. Singh SK,. 2011. Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci 100 (2): 354-387.
4. Schellekens H, Casadevall N,. 2004. Immunogenicity of recombinant human proteins: Causes and consequences. J Neurol 251 Suppl 2: II4-II9.
5. Schellekens H., 2005. Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract Res Clin Haematol 18 (3): 473-480.
6. Carson KR, Evens AM, Bennett CL, Luminari S,. 2005. Clinical characteristics of erythropoietin-associated pure red cell aplasia. Best Pract Res Clin Haematol 18 (3): 467-472.
7. de Vries MK, Brouwer E, van der Horst-Bruinsma IE, Spoorenberg A, van Denderen JC, Jamnitski A, Nurmohamed MT, Dijkmans BA, Aarden LA, Wolbink GJ,. 2009. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann Rheum Dis 68 (11): 1787-1788.
8. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P,. 2002. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346 (7): 469-475.
9. Grossberg SE, Oger J, Grossberg LD, Gehchan A, Klein JP,. 2011. Frequency and magnitude of interferon beta neutralizing antibodies in the evaluation of interferon beta immunogenicity in patients with multiple sclerosis. J Interferon Cytokine Res 31 (3): 337-344.
10. Gribben JG, Devereux S, Thomas NSB, Keim M, Jones HM, Goldstone AH, Linch DC,. 1990. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 335: 434-437.
11. Braun A, Kwee L, Labow MA, Alsenz J,. 1997. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res 14 (10): 1472-1478.
12. Kijanka G, Jiskoot W, Schellekens H, Brinks V,. 2013. Effect of treatment regimen on the immunogenicity of human interferon beta in immune tolerant mice. Pharm Res 30: 1553-1160.
13. Barbosa MD, Vielmetter J, Chu S, Smith DD, Jacinto J,. 2006. Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity. Clin Immunol 118 (1): 42-50.
14. Hwang WY, Foote J,. 2005. Immunogenicity of engineered antibodies. Methods 36 (1): 3-10.
15. Fradkin AH, Carpenter JF, Randolph TW,. 2011. Glass particles as an adjuvant: A model for adverse immunogenicity of therapeutic proteins. J Pharm Sci 100 (11): 4953-4964.
16. Barnard JG, Babcock K, Carpenter JF,. 2013. Characterization and quantitation of aggregates and particles in interferon-beta products: Potential links between product quality attributes and immunogenicity. J Pharm Sci 102 (3): 915-928.
17. Ross C, Clemmesen KM, Svenson M, Sorensen PS, Koch-Henriksen N, Skovgaard GL, Bendtzen K, Group DMSS. 2001. Immunogenicity of interferon-B in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration. Ann Neurol 48 (5): 706-712.
18. Smiell JM, Schellekens H, Crommelin DJ,. 2003. Equivocal role of micelles in Eprex adverse events. Nat Biotechnol 21: 1265.
19. Casadevall N, Rossert J,. 2005. Importance of biologic follow-ons: Experience with EPO. Best Pract Res Clin Haematol 18 (3): 381-387.
20. Peng A, Gaitonde P, Kosloski MP, Miclea RD, Varma P, Balu-Iyer SV,. 2009. Effect of route of administration of human recombinant factor VIII on its immunogenicity in hemophilia A mice. J Pharm Sci 98 (12): 4480-4484.
21. Peng A, Kosloski MP, Nakamura G, Ding H, Balu-Iyer SV,. 2012. PEGylation of a factor VIII-phosphatidylinositol complex: Pharmacokinetics and immunogenicity in hemophilia A mice. AAPS J 14 (1): 35-42.
22. Bachmann MF, Zinkernagel RM,. 1997. Neutralizing antiviral B cell responses. Annu Rev Immunol 15: 235-270.
23. Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL,. 1993. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci USA 90: 4942-4946.
24. Bachmann MF, Jennings GT,. 2010. Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 10 (11): 787-796.
25. +T-cells and apparent lack of immunological memory. J Clin Immunol 33 (1): 255-263.
26. Rosenberg AS., 2006. Effects of protein aggregates: An immunologic perspective. AAPS J 8 (3): E501-E507.
27. Dintzis HM, Dintzis RZ, Volgelstein B,. 1976. Molecular determinants of immunogenicity: The immunon model of immune response. Proc Natl Acad Sci USA 73 (10): 3671-3675.
28. Cox JC, Coulter AR,. 1997. Adjuvants-A classification and review of their modes of action. Vaccine 15 (3): 2488-2256.
29. Fradkin AH, Boand CS, Eisenberg SP, Rosendahl MS, Randolph TW,. 2010. Recombinant murine growth hormone from E. coli inclusion bodies: Expression, high-pressure solubilization and refolding, and characterization of activity and structure. Biotechnol Prog 26 (3): 743-749.
30. Singh SM, Upadhyay AK, Panda AK,. 2008. Solubilization at high pH results in improved recovery of proteins from inclusion bodies of E. coli. J Chem Technol Biotechnol 83 (8): 1126-1134.
31. Bewley TA, Li CH,. 1972. Molecular weight and circular dichroism studies of bovine and ovine pituitary growth hormones. Biochemistry 11 (5): 927-931.
32. Mulinacci F, Capelle MA, Gurny R, Drake AF, Arvinte T,. 2011. Stability of human growth hormone: Influence of methionine oxidation on thermal folding. J Pharm Sci 100 (2): 451-463.
33. Buijs J, Hlady V,. 1997. Adsorption kinetics, conformation, and mobility of the growht hormone and lysozyme on solid surfaces, studied with TIRF. J Colloid Interface Sci 190 (1): 171-181.
34. Barnard JG, Singh S, Randolph TW, Carpenter JF,. 2011. Subvisible particle counting provides a sensitive method of detecting and quantifying aggregation of monoclonal antibody caused by freeze-thawing: Insights into the roles of particles in the protein aggregation pathway. J Pharm Sci 100 (2): 492-503.
35. Frey A, Di Canzio J, Zurakowski D,. 1998. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods 221: 35-41.
36. Natsuume-Sakai S., Motonishi K., Migita S,. 1977. Quantitative estimation of five classes of immunoglobulin in inbred mouse strains. Immunology 32: 861-866.
37. Martin JB, Renaud LP, Brazeau Jr P,. 1974. Pulsatile growth hormone secretion: Suppression by hypothalamic ventromedial lesions and by long-acting somatostatin. Science 186 (4163): 538-540.
38. Hwang DL, Lee PD, Cohen P,. 2008. Quantitative ontogeny of murine insulin-like growth factor (IGF)-I, IGF-binding protein-3 and the IGF-related acid-labile subunit. Growth Horm IGF Res 18 (1): 65-74.
39. Yamada PM, Mehta HH, Hwang D, Roos KP, Hevener AL, Lee KW,. 2010. Evidence of a role for insulin-like growth factor binding protein (IGFBP)-3 in metabolic regulation. Endocrinology 151 (12): 5741-5750.
40. Laboratories, CR, 2013. CB6F1 Mouse.Charles River. [Online]. Available: http://www.criver.com/products-services/basic-research/find-a-model/cb6f1-mouse [2013, August 22].
41. Singh SK, Afonina N, Awwad M, Bechtold-Peters K, Blue JT, Chou D, Cromwell M, Krause HJ, Mahler HC, Meyer BK, Narhi L, Nesta DP, Spitznagel T,. 2010. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. J Pharm Sci 99 (8): 3302-3321.
42. Stevens TL, Bossie A, Sanders VM, Fernandez-Botran R, Coffman RL, Mosmann TR, Vitetta ES,. 1988. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 334: 225-258.
43. Snapper CM, McIntyre TM, Mandler R, Pecanha LM, Finkelman FD, Lees A, Mond JJ,. 1992. Induction of IgG3 secretion by interferon gamma: A model for T cell-independent class switching in response to T cell-independent type 2 antigens. J Exp Med 175 (5): 1367-1371.
44. Humphrey JH,. 1985. Splenic macrophages: Antigen presenting cells for T1-2 antigens. Immunol Lett 11: 149-152.
45. Massa G, Vanderschueren-Lodeweyckx M, Bouillon R,. 1993. Five-year follow-up of growth hormone antibodies in growth hormone deficient children treated with recombinant human growth hormone. Clin Endocrinol 38 (2): 137-142.
46. Pirazzoli P, Cacciari E, Mandini M, Cicognani A, Zucchini S, Sganga T, Capelli M,. 2008. Follow-up of antibodies to growth hormone in 210 growth hormone-deficient children treadted with different commerical preparations. Acta Paediatr 84: 1233-1236.
47. Buzi F, Buchanan CR, Morrell DJ, Preece MA,. 2008. Antigenicity and efficacy of authentic sequence recombinant human growth hormone (somatropin): First-year experience in the United Kingdom. Clin Endocrinol 30 (5): 531-538.
48. Rougeot C, Marchand PM, Dray F, Girard F, Job JC, Pierson M, Ponte C, Rochiccioli P, Rappaport R,. 1991. Comparative study of biosynthetic human growth hormone immunogenicity in growth hormone deficient children. Horm Res Paediatr 35 (2): 76-81.
49. Spellberg B, Edwards Jr. JE,. 2001. Type 1/type 2 immunity in infectious diseases. Clin Infect Dis 32: 76-102.
50. Bungener L, Geeraedts F, Ter Veer W, Medema J, Wilschut J, Huckriede A,. 2008. Alum boosts Th2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 26 (19): 2350-2359.
51. Mannhalter JW, Neychev HO, Zlabinger GJ, Ahmad R, Eibl MM,. 1985. Modulation of hte human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: Effect on antigen uptake and antigen presentation. Clin Exp Immunol 61: 143-151.
52. Babiuk S, Skowronski DM, De Serres G, HayGlass K, Brunham RC, Babiuk L,. 2004. Aggregate content influences the Th1/Th2 immune response to influenza vaccine: Evidence from a mouse model. J Med Virol 72 (1): 138-142.
53. Vos Q, Lees A, Wu Z-Q, Snapper CM, Mond JJ,. 2000. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol Rev 176: 154-170.
54. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF,. 2008. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 38 (5): 1404-1413.
55. Roozendaal R, Mempel TR, Pitcher LA, Gonzalez SF, Verschoor A, Mebius RE, von Andrian UH, Carroll MC,. 2009. Conduits mediate transport of low-molecular-weight antigen to lymph node follicles. Immunity 30 (2): 264-276.
56. Eggert AAO, Schreurs MWJ, Boerman OC, Oyen WJC, de Boer AJ, Punt CJA, Figdor CG, Adema GJ,. 1999. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 59: 3340-3345.
57. Anjuere G, Martin P, Ferrero I, Fraga ML, del Hoyo GM, Wright N, Ardavin C,. 1999. Definition of dendritic cell subpopulations present in the spleen, peyer's patches, lymph nodes, and skin of the mouse. Blood 93 (2): 590-598.
58. - subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J Exp Med 189 (3): 587-592.
59. Moser M, Murphy KM,. 2000. Dendritic cell regulation of Th1-Th2 development. Nat Immunol 1 (3): 199-205.
60. Brown JC, Harris G, Papamichail M, Sljivic VS, Holborow EJ,. 1973. The localization of aggregated human gamma-globulin in the spleens of normal mice. Immunology 24: 955-968.
61. Batista FD, Harwood NE,. 2009. The who, how and where of antigen presentation to B cells. Nat Rev Immunol 9 (1): 15-27.
62. Martin F, Kearney JF,. 2002. Marginal-zone B cells. Nat Rev Immunol 2 (5): 323-335.
63. Attanavanich K, Kearney JF,. 2004. Marginal zone, but not follicular B cells are potent activators of naive CD4 T cells. J Immunol 172: 803-811.
64. Balazs M, Martin F, Zhou T, Kearney JF,. 2002. Blood dendritic cells interaction with splenic marginal zone b cells to initiate T-independent immune responses. Immunity 17: 341-352.
65. Mebius RE, Kraal G,. 2005. Structure and function of the spleen. Nat Rev Immunol 5 (8): 606-616.
66. Kearney JF, Lopes-Caravalho T,. 2004. Development and selection of marginal zone B cells. Immunol Rev 197: 192-205.
67. Mongini P, Stein KE, Paul WE,. 1981. T cell regulation of IgG subclass antibody production in response to T-independent antigens. J Exp Med 153: 1-12.